Skip to main content

Table 2 Product related impurities of purified bulk BK0023 preparations

From: Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®

Impurity

Method

Result

BK0023 oxydized forms

RP-HPLC

< 1%

BK0023 aggregate forms

SE-HPLC

< 1%

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us